Beyond inflammation: Tolerance, immunotherapy and more

European Journal of Dermatology

Volumn 9, Issue 6, 1999, Pages 507-514

  Goerdt, Sergij ^a   Birk, Robert ^a   Dippel, Edgar ^a   Orfanos, Constantin E ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; DNA; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MPL; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; ATOPIC DERMATITIS; COST EFFECTIVENESS ANALYSIS; GENE THERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PSORIASIS; SKIN ALLERGY; SKIN INFLAMMATION;

EID: 0032829992     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Wilckens T, De Rijk R. Glucocorticoids and immune function unknown dimensions and new frontiers. Immunol Today 1997; 18: 418-24.
2. Dierynck I, Bernard A, Roels H, De Ley M. The human Clara cell protein: biochemical and biological characterization of a natural immunosuppressor. Mult Scler 1996; 1: 385-7.
3. Dierynck I, Bernard A, Roels H, De Ley M. Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16. Am J Respir Cell Mol Biol 1995; 12: 205-10.
4. Weiss M. Anstieg respiratorischer Krankheiten: Übeltäter Rauchen und Asthma. Deutsches Ärzteblatt 1998; 95: A-4.
5. bright monocytic/macrophagic cells. J Immunol 1994; 153: 4915-24.
6. Stevens SR, Shibaki A, Meunier L, Cooper KD. Suppressor T cell-activating macrophages in ultraviolet-irradiated human skin induce a novel, TGF-b-dependent form of T cell activation characterized by deficient IL-2Ra expression. J Immunol 1995; 155: 5601-7.
7. Holt PG. Immunoprophylaxis of atopy: light at the end of the tunnel? Immunol Today 1994; 15: 484-9.
8. Field EH, Gao Q, Chen N, Rouse TM. Balancing the immune system for tolerance. Transplantation 1997; 64: 1-7.
9. + T cell subsets and cytokines involved in peripheral tolerance. Immunol Today 1997; 18: 533-8.
10. Liu Y. Is CTLA-4 a negative regulator for T cell activation? Immunol Today 1997; 18: 569-72.
11. Strobel S, Mowat AM. Immune responses to dietary antigens, oral tolerance. Immunol Today 1998; 19: 173-81.
12. + T helper type 2 cells. J Exp Med 1996; 183: 759-68.
13. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18: 335-43.
14. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid-specific transforming growth factor-b1-secreting Th3 cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996; 98: 70-7.
15. Kennedy KJ, Smith WS, Miller SD, Karpus WJ. Induction of antigen-specific tolerance for the treatment of ongoing, relapsing autoimmune encephalomyelitis. A comparison between oral and peripheral tolerance. J Immunol 1997; 159: 1036-44.
16. Grabbe S, Schwarz T. Immunoregulatory mechanisms invovled in elicitation of allergic contact hypersensitivity. Immunol Today 1998; 19: 37-44.
17. Bouloc A, Cavani A, Katz SI. Contact hypersensitivity in MHC class II-deficient mice depends on CD8 T lymphocytes primed by immunostimulating Langerhans cells. J Invest Dermatol 1998; 111: 44-9.
18. + T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur J Immunol 1995; 25: 3006-10.
19. Stein M, Keshav S, Harris N, Gordon S. Interleukin-4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
20. Goerdt S, Walsh LJ, Murphy GF, Pober JS. Identification of a novel high molecular weight protein antigen preferentially expressed by sinusoidal endothelial cells in normal human tissues. J Cell Biol 1991; 113: 1425-37.
21. + dermal perivascular dendritic cells. Lab Invest 1991; 65: 732-41.
22. Goerdt S, Bhardwaj R, Sorg C. Inducible expression of MS-1 high molecular weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am J Pathol 1993; 142: 1409-22.
23. Goerdi S, Kolde G, Bonsmann G, Hamann K, Czarnetzki B, Andreesen R, Luger T, Sorg C. Immunohistochemical comparison of cutaneous histiocytoses and related skin disorders: diagnostic and histogenetic relevance of MS-1 high molecular weight protein expression. J Pathol 1993; 170: 421-7.
24. Zwadlo G, Voegeli R, Schulze-Osthoff K, Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol 1987; 55: 295-304.
25. Wenzel I, Roth J, Sorg C. Identification of a novel surface molecule, RM 3/1, that contributes to the adhesion of glucocorticoid-induced human monocytes to endotheliol cells. Eur J Immunol 1996; 26: 2758-63.
26. Goerdt S, Kodelja V, Schmuth M, Orfanos CE, Sorg C. The mononuclear phagocyte-dendritic cell dichotomy: myths, facts, and a revised concept. Clin Exp Immunol 1996; 105: 1-9.
27. Kodelja V, Goerdt S. Dissection of macrophage differentiation pathways in cutaneous macrophage disorders and in vitro. Exp Dermatol 1994; 3: 257-68.
28. Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayon G, Koch AE. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 221-31.
29. - in psoriatic dermis. Arch Dermatol Res 1996; 288: 757-64.
30. Kodelja V, Müller C, Tenorio S, Schebesch C, Orfanos CE, Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiol 197: 478-93.
31. + T cells in vitro. Immunol 1997; 92: 478-86.
32. Kodelja V, Müller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-l a with a Th2-associated expression pattern. J Immunol 1998; 160: 1411-8.
33. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T, Bacon KB, Figdor CG. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387: 713-7.
34. + Longerhans -like dendritic ontigen-presenting cells are concomittantly depleted. J Invest Dermatol 1995; 105: 782-8.
35. Takeuchi M, Kosiewicz MM, Alard P, Streilein JW. On the mechanism by which transforming growth factor-b2 alters antigen-presenting abilities of macrophages on T cell activation. Eur J Immunol 1997; 27: 1648-56.
36. Hoyne G, Bourne T, Kristensen N, Hetzel C, Lamb J. From epitopes to peptides to immunotherapy. Clin Immunol Immunopathol 1996; 80: S23-30.
37. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Thl shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27: 1131-9.
38. Yamashita N, Takeno M, Kaneko S, Mizushima Y, Sakane T. Therapeutic effects of preferential induction of mite-specific T helper 0 clones. Clin Exp Imunol 1997; 109: 332-41.
39. + T cell responses. Int Immunol 1997; 2; 273-80.
40. Hsu CH, Chua KY, Too MH, Lai YL, Wu HD, Huang SK, Hsieh KH. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1997; 2: 540-4.
41. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351: 629-32.
42. Holt PG, Sly PD, Smith W. Sublingual immunotherapy For allergic respiratory disease. Lancet 1998; 351: 613-4.
43. Yasue M, Yokota T, Kajiwara Y, Suko M, Okudaira H. Inhibition of airway inflammation in rDer f 2-sensitized mice by oral administration of recombinant Der f 2. Cell Immunol 1997; 181: 30-7.
44. Austrup F, Vestweber D, Borges E, Löhning M, Bräuer R, Herz U, Renz H, Hallmann R, Scheffold A, Rodbruch A, Hamann A. P- and E- selection mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 1997; 385: 81-3.
45. Wheeler AW, Drachenberg KJ. New routes and formulations for allergen-specific immunotherapy. Allergy 1997; 52: 602-12.
46. Spiegelberg HL, Orozco EM, Roman M, Raz E. DNA immunization: a novel approach to allergen-specific immunotherapy. Allergy 1997; 52: 964-70.
47. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R. Conversion of the major birch pollen allergen, Bet v I, into two nonanaphylactic T cell epitope-containing fragments. J Clin Invest 1997; 99: 1673-81.
48. Thomas WR, Smith W, Hales BJ. House dust mite allergen characterization: implications for T cell responses and immunotherapy. Int Arch Allergy Immunol 1998; 115: 9-14.
49. Larché M. T cell responses to house dust mites: bad news for immunotherapy? Clin Exp Allergy 1997; 27: 853-5.
50. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA. Preferential induction of a Th1 imune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93: 5141-5.
51. Tighe H, Carr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998; 19: 89-97.
52. Moelling K. DNA for genetic vaccination and therapy. Cytokines, Cellular and Molecular Therapy 1997; 3: 127-36.
53. Slater JE, Colberg-Poley A. A DNA vaccine for allergen immunotherapy using the Latex allergen Hev b 5. In: Arbeiten aus dem Paul Ehrlich Institut, Band 91, 8th International Paul Ehrlich Seminar. Anonymous-Gustav Fischer Verlag, Stuttgart Jena Lübeck Ulm, 1997: 230-5.
54. Des Roches A, Paradis L, Menardo JL, Bouges S, Daurès JP, Bousquet J. Immunotherapy with standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99: 450-3.
55. Rudolf MP, Vogel M, Kricek F, Ruf C, Zürcher AW, Reuschel R, Auer M, Miescher S, Stadler BM. Epitope-specific antibody response to IgE by mimotope immunization. J Immunol 1998; 160: 3315-21.
56. Shirakawa T, Enomoto T, Shimazu SI, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997; 275: 77-9.
57. Cookson WOCM, Moffatt MF. Asthma: an epidemic in the absence of infection? Science 1997; 275: 41-2.
58. Wang CC, Rook GAW. Inhibition of an established allergic response to ovalbumin in Balb/c mice by killed Mycobacterium vaccoe. Immunol 1998; 93: 307-13.
59. Rook GAW, Stanford JL. Give us this day our daily germs. Immunol Today 1998; 19: 113-6.
60. Alm JS, Lilja G, Pershagen G, Scheynius A. Early BCG vaccination and development of atopy. Lancet 1997; 350: 400-3.
61. Kling J. IL-4 may unlock asthma and allergic diseases. Nat Biotechnol 1997; 15: 316-7.